References

Unresolved reference

2006 · External reference

Unresolved reference

2021 · External reference

Unresolved reference

External reference

Unresolved reference

2020 · External reference

Unresolved reference

2017 · External reference

Unresolved reference

2016 · External reference

Unresolved reference

2024 · External reference

Ivermectin dose assessment without weighing scales

1993 · External reference

The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin

1995 · External reference

Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly

10.1016/j.trstmh.2003.10.018 · 2004 · External reference

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach

2019 · External reference

An improved dosing schedule for ivermectin as a microfilaricidal agent against onchocerciasis

10.1016/s0001-706x(97)00101-0 · 1997 · External reference

O24 Ivermectin in children: what is the right dose to achieve equivalent exposure coverage in children and adults?

10.1136/archdischild-2019-esdppp.24 · 2019 · External reference

A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?

10.1371/journal.pntd.0009144 · 2021 · External reference

Safety of high-dose ivermectin: a systematic review and meta-analysis

10.1093/jac/dkz524 · 2020 · External reference

Efficacy and Safety of Albendazole and High-Dose Ivermectin Coadministration in School-Aged Children Infected With Trichuris trichiura in Honduras: A Randomized Controlled Trial

10.1093/cid/ciab365 · 2021 · External reference

Albendazole-ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial

10.1016/s1473-3099(24)00669-8 · 2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

2016 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Conducting meta-analyses in R with the metafor package

2010 · External reference

Unresolved reference

2021 · External reference

Unresolved reference

1995 · External reference

Albendazole and ivermectin for the control of soil-transmitted helminths in an area with high prevalence of Strongyloides stercoralis and hookworm in northwestern Argentina: A community-based pragmatic study

10.1371/journal.pntd.0006003 · 2017 · External reference

Unresolved reference

2020 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar

10.4269/ajtmh.19-0179 · 2019 · External reference

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

10.1056/nejmoa0903627 · 2010 · External reference

Ambisome plus miltefosine for Indian patients with kala-azar

10.1016/j.trstmh.2010.10.008 · 2011 · External reference

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

10.1086/591972 · 2008 · External reference

Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment

10.1086/605438 · 2009 · External reference

Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis

10.1155/2015/414378 · 2015 · External reference

Ambisome plus miltefosine for Indian patients with kala-azar

10.1016/j.trstmh.2010.10.008 · 2011 · External reference

Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study

10.4269/ajtmh.14-0259 · 2015 · External reference

Injectable paromomycin for Visceral leishmaniasis in India

10.1056/nejmoa066536 · 2007 · External reference

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

10.1016/s0140-6736(10)62050-8 · 2011 · External reference

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

10.1093/cid/cis474 · 2012 · External reference

Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent

10.7554/elife.12613 · 2016 · External reference

Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan

10.1186/s12936-018-2266-9 · 2018 · External reference

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

10.1016/s0140-6736(19)31285-1 · 2019 · External reference

Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India

10.1186/1475-2875-11-97 · 2012 · External reference

Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy

10.1093/jac/dkz098 · 2019 · External reference

Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria

10.1186/1475-2875-10-380 · 2011 · External reference

A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania

10.1186/s12936-022-04100-1 · 2022 · External reference

Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether-Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania

10.4269/ajtmh.18-0729 · 2019 · External reference

A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial

2011 · External reference

Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam

10.1128/aac.02746-14 · 2014 · External reference

Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial

10.1016/s1473-3099(22)00658-2 · 2023 · External reference

Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo

10.1186/s12916-023-03105-0 · 2023 · External reference

A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya

10.1186/1475-2875-7-262 · 2008 · External reference

Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan

10.1186/1475-2875-11-404 · 2012 · External reference

Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial

10.1016/s2214-109x(18)30397-8 · 2018 · External reference

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial

2014 · External reference

Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda

10.1179/136485908x252142 · 2008 · External reference

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

2010 · External reference

Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial

10.1371/journal.pntd.0001674 · 2012 · External reference

Integrated genomic and metabolomic profiling of ISC1, an emerging Leishmania donovani population in the Indian subcontinent

10.1016/j.meegid.2018.04.021 · 2018 · External reference

Single locus genotyping to track Leishmania donovani in the Indian subcontinent: Application in Nepal

2017 · External reference

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance

10.1101/gr.123430.111 · 2011 · External reference

Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal

10.1016/j.trstmh.2009.08.002 · 2010 · External reference

Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

10.1016/j.micinf.2007.01.009 · 2007 · External reference

Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal

10.1016/j.meegid.2006.08.005 · 2007 · External reference

The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine

10.4269/ajtmh.2005.73.272 · 2005 · External reference

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial

10.1371/journal.pntd.0000709 · 2010 · External reference

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

10.1086/519690 · 2007 · External reference

Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India

10.4269/ajtmh.17-0094 · 2017 · External reference

The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians

10.1186/s12879-019-3862-1 · 2019 · External reference

Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial

10.1371/journal.pmed.1002299 · 2017 · External reference

G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study

2016 · External reference

Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

10.1186/s12936-015-0938-2 · 2015 · External reference

Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial

10.1086/599378 · 2009 · External reference

A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam

10.4269/ajtmh.15-0740 · 2016 · External reference

Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

10.1186/s12936-019-3015-4 · 2019 · External reference

Four Artemisinin-Based Treatments in African Pregnant Women with Malaria

10.1056/nejmoa1508606 · 2016 · External reference

Human placental extract offers protection against experimental visceral leishmaniasis: a pilot study for a phase-I clinical trial

10.1179/136485908x252133 · 2008 · External reference

A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India

2009 · External reference

Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India

10.4269/ajtmh.16-0242 · 2016 · External reference

Unresolved reference

2022 · External reference

Unresolved reference

External reference

Unresolved reference

2021 · External reference

Unresolved reference

2020 · External reference

Unresolved reference

2020 · External reference

Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study

10.1371/journal.pntd.0003169 · 2014 · External reference

Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar

10.1111/j.1365-3156.2008.02128.x · 2008 · External reference

Unresolved reference

External reference

10.1186/s40249-023-01054-7

10.1186/s40249-023-01054-7 · 2023 · External reference

High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial

10.1016/j.ijantimicag.2021.106516 · 2022 · External reference

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects

10.1177/009127002237994 · 2002 · External reference

Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?

10.4269/ajtmh.17-0042 · 2018 · External reference

Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations

10.1056/nejmc1917344 · 2020 · External reference

Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years

10.1093/jac/dkz083 · 2019 · External reference

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

10.1016/s0140-6736(20)30925-9 · 2020 · External reference

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases

2008 · External reference

Standardized method to assess medicines’ acceptability: focus on paediatric population

10.1111/jphp.12547 · 2017 · External reference

Paediatric drug optimization for neglected tropical diseases: meeting report, September 2023

2023 · External reference